|
MA42456B1
(fr)
*
|
2015-06-25 |
2021-06-30 |
Univ Health Network |
Inhibiteurs de hpk1 et leurs procédés d'utilisation
|
|
US10280164B2
(en)
|
2016-09-09 |
2019-05-07 |
Incyte Corporation |
Pyrazolopyridone compounds and uses thereof
|
|
WO2018049214A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
|
|
CN115819417A
(zh)
|
2016-09-09 |
2023-03-21 |
因赛特公司 |
作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
|
|
US20180072741A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyrimidine compounds and uses thereof
|
|
WO2018152220A1
(en)
*
|
2017-02-15 |
2018-08-23 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
|
CN110402248B
(zh)
*
|
2017-03-15 |
2023-01-06 |
豪夫迈·罗氏有限公司 |
作为hpk1抑制剂的氮杂吲哚类
|
|
EP3601259B1
(en)
|
2017-03-30 |
2022-02-23 |
F. Hoffmann-La Roche AG |
Isoquinolines as inhibitors of hpk1
|
|
AU2018244935A1
(en)
*
|
2017-03-30 |
2019-08-15 |
F. Hoffmann-La Roche Ag |
Naphthyridines as inhibitors of HPK1
|
|
WO2018228925A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
EP3638670B1
(en)
|
2017-06-13 |
2021-07-21 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
|
|
EP3638669A1
(en)
|
2017-06-13 |
2020-04-22 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
CA3070013A1
(en)
|
2017-07-18 |
2019-01-24 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
US10722495B2
(en)
|
2017-09-08 |
2020-07-28 |
Incyte Corporation |
Cyanoindazole compounds and uses thereof
|
|
CN109721620B
(zh)
*
|
2017-10-27 |
2022-05-13 |
药捷安康(南京)科技股份有限公司 |
Hpk1抑制剂及其用途
|
|
EP3707138B1
(en)
*
|
2017-11-06 |
2022-07-13 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
EP3755703B1
(en)
*
|
2018-02-20 |
2022-05-04 |
Incyte Corporation |
N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
|
|
US10745388B2
(en)
|
2018-02-20 |
2020-08-18 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US10752635B2
(en)
|
2018-02-20 |
2020-08-25 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US11299473B2
(en)
|
2018-04-13 |
2022-04-12 |
Incyte Corporation |
Benzimidazole and indole compounds and uses thereof
|
|
TW202012405A
(zh)
*
|
2018-07-24 |
2020-04-01 |
瑞士商赫孚孟拉羅股份公司 |
萘啶化合物及其用途
|
|
TW202019905A
(zh)
|
2018-07-24 |
2020-06-01 |
瑞士商赫孚孟拉羅股份公司 |
異喹啉化合物及其用途
|
|
US10899755B2
(en)
|
2018-08-08 |
2021-01-26 |
Incyte Corporation |
Benzothiazole compounds and uses thereof
|
|
WO2020068729A1
(en)
|
2018-09-25 |
2020-04-02 |
Incyte Corporation |
Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
|
|
TW202024053A
(zh)
|
2018-10-02 |
2020-07-01 |
美商建南德克公司 |
異喹啉化合物及其用途
|
|
US11612606B2
(en)
|
2018-10-03 |
2023-03-28 |
Genentech, Inc. |
8-aminoisoquinoline compounds and uses thereof
|
|
WO2020072695A1
(en)
*
|
2018-10-03 |
2020-04-09 |
Genentech, Inc. |
8-aminoisoquinoline compounds and uses thereof
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
US11203591B2
(en)
|
2018-10-31 |
2021-12-21 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds
|
|
WO2020120257A1
(en)
|
2018-12-11 |
2020-06-18 |
Bayer Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
WO2020132384A1
(en)
|
2018-12-21 |
2020-06-25 |
Celgene Corporation |
Thienopyridine inhibitors of ripk2
|
|
WO2020135483A1
(en)
*
|
2018-12-26 |
2020-07-02 |
Janssen Pharmaceutica Nv |
Thienopyridinone compounds
|
|
US12492194B2
(en)
|
2019-03-26 |
2025-12-09 |
Janssen Pharmaceutica Nv |
HPK1 inhibitors
|
|
US12486264B2
(en)
|
2019-03-26 |
2025-12-02 |
Janssen Pharmaceutica Nv |
Bicyclic HPK1 inhibitors
|
|
WO2020235902A1
(ko)
*
|
2019-05-17 |
2020-11-26 |
주식회사 보로노이 |
헤테로고리 융합 피리미딘 유도체 및 이의 용도
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
WO2020263830A1
(en)
|
2019-06-25 |
2020-12-30 |
Gilead Sciences, Inc. |
Flt3l-fc fusion proteins and methods of use
|
|
TWI848141B
(zh)
|
2019-07-04 |
2024-07-11 |
英屬開曼群島商百濟神州有限公司 |
及其用途
|
|
US12459958B2
(en)
|
2019-07-17 |
2025-11-04 |
Beone Medicines I Gmbh |
Tricyclic compounds as HPK1 inhibitor and the use thereof
|
|
BR112022002059A2
(pt)
|
2019-08-06 |
2022-06-07 |
Incyte Corp |
Formas sólidas de um inibidor de hpk1
|
|
MX2022002877A
(es)
*
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
|
CN112552293A
(zh)
*
|
2019-09-25 |
2021-03-26 |
珠海宇繁生物科技有限责任公司 |
一种protac小分子化合物及其应用
|
|
ES2973832T3
(es)
|
2019-10-18 |
2024-06-24 |
Forty Seven Inc |
Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
|
|
JP2022552748A
(ja)
|
2019-10-31 |
2022-12-19 |
フォーティ セブン， インコーポレイテッド |
抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
IL294032A
(en)
|
2019-12-24 |
2022-08-01 |
Carna Biosciences Inc |
Compounds that regulate diacylglycerol kinase
|
|
JP7667745B2
(ja)
*
|
2020-01-09 |
2025-04-23 |
住友化学株式会社 |
複素環化合物及びそれを含有する有害節足動物防除組成物
|
|
TWI890283B
(zh)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
CN115867275A
(zh)
*
|
2020-04-13 |
2023-03-28 |
大学健康网络 |
治疗细胞因子释放综合征的方法
|
|
IL297327B2
(en)
|
2020-05-01 |
2026-01-01 |
Gilead Sciences Inc |
4,2-dioxopyrimidine compounds CD73 inhibitors
|
|
KR20230019110A
(ko)
*
|
2020-05-11 |
2023-02-07 |
유니버시티 헬스 네트워크 |
4-아미노-5-(6-(4-메틸피페라진-1-일)-1H-벤조[D]이미다졸-2-일)티에노[2,3-b]피리딘-6(7H)-온(one)의 염 및 결정형
|
|
WO2021249913A1
(en)
|
2020-06-09 |
2021-12-16 |
Bayer Aktiengesellschaft |
2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
|
|
CN113845531B
(zh)
*
|
2020-06-28 |
2025-06-27 |
四川科伦博泰生物医药股份有限公司 |
吡唑并环类化合物、包含其的药物组合物、其制备方法及其用途
|
|
WO2022064459A1
(en)
*
|
2020-09-28 |
2022-03-31 |
1ST Biotherapeutics, Inc. |
Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
|
|
HRP20260277T1
(hr)
*
|
2020-09-30 |
2026-04-10 |
Beone Medicines I Gmbh |
Spojevi 3-[(1h-pirazol-4-il)oksi]pirazin-2-amina kao inhibitori hpk1 i njihova upotreba
|
|
US20230406864A1
(en)
*
|
2020-11-09 |
2023-12-21 |
Merck Sharp & Dohme Llc |
7-azole substituted 2-aminoquinazoline inhibitors of hpk1
|
|
US20240002394A1
(en)
*
|
2020-11-24 |
2024-01-04 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Deuterium-modified thienopyridone compound
|
|
CN121851009A
(zh)
*
|
2021-01-22 |
2026-04-14 |
苏州信诺维医药科技股份有限公司 |
Hpk1抑制剂、其制备方法、药物组合物及其应用
|
|
US20240174683A1
(en)
|
2021-02-05 |
2024-05-30 |
Bayer Aktiengesellschaft |
Map4k1 inhibitors
|
|
CN114907377A
(zh)
*
|
2021-02-10 |
2022-08-16 |
江苏恒瑞医药股份有限公司 |
稠合四环类化合物、其制备方法及其在医药上的应用
|
|
EP4291235A4
(en)
|
2021-02-12 |
2025-01-08 |
Nimbus Saturn, Inc. |
HPK1 ANTAGONISTS AND USES THEREOF
|
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
TW202246284A
(zh)
*
|
2021-03-10 |
2022-12-01 |
大陸商山東軒竹醫藥科技有限公司 |
三并環類hpk1抑制劑及其用途
|
|
WO2022199676A1
(zh)
*
|
2021-03-26 |
2022-09-29 |
江苏恒瑞医药股份有限公司 |
稠合四环类化合物、其制备方法及其在医药上的应用
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
US20240425479A1
(en)
*
|
2021-04-30 |
2024-12-26 |
Ontario Institute For Cancer Research (Oicr) |
Halo-substituted amino aza-heteroaryl compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)
|
|
JP2024517771A
(ja)
*
|
2021-04-30 |
2024-04-23 |
オンタリオ・インスティテュート・フォー・キャンサー・リサーチ（オーアイシーアール） |
造血前駆キナーゼ１（ｈｐｋ１）の阻害剤としての置換アミノアザヘテロアリール化合物
|
|
WO2022226667A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Ontario Institute For Cancer Research (Oicr) |
Substituted amino pyridine compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
WO2022253252A1
(en)
*
|
2021-06-03 |
2022-12-08 |
Silexon Biotech Co., Ltd. |
Heterocyclic compounds useful as hpk1 inhibitors
|
|
CN115433161A
(zh)
*
|
2021-06-04 |
2022-12-06 |
轶诺(浙江)药业有限公司 |
新型hpk1抑制剂及其制备方法和应用
|
|
WO2022258044A1
(zh)
*
|
2021-06-11 |
2022-12-15 |
杭州中美华东制药有限公司 |
吡咯并吡啶酮类化合物及其制备方法和用途
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
JP7686091B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
WO2023288254A1
(en)
*
|
2021-07-14 |
2023-01-19 |
Blueprint Medicines Corporation |
Heterocyclic compounds as map4k1 inhibitors
|
|
TW202321239A
(zh)
|
2021-07-20 |
2023-06-01 |
瑞典商阿斯特捷利康公司 |
作為ｈｐｋ１抑制劑用於治療癌症之經取代的吡𠯤—２—甲醯胺
|
|
WO2023015199A1
(en)
*
|
2021-08-03 |
2023-02-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
WO2023023942A1
(en)
*
|
2021-08-24 |
2023-03-02 |
Biofront Ltd (Cayman) |
Hpk1 inhibitors, compositions comprising hpk1 inhibitor, and methods of using the same
|
|
TW202327595A
(zh)
*
|
2021-10-05 |
2023-07-16 |
美商輝瑞大藥廠 |
用於治療癌症之氮雜內醯胺化合物的組合
|
|
EP4416146A4
(en)
*
|
2021-10-15 |
2025-11-05 |
Lomond Therapeutics Inc |
1H-PYRAZOLO[4,3-C]QUINOLINE SUBSTITUTES, THEIR PREPARATION PROCESSES AND THEIR USE
|
|
AU2022375782B2
(en)
|
2021-10-28 |
2026-02-26 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP7787991B2
(ja)
|
2021-10-29 |
2025-12-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
WO2023107956A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
CN118339168A
(zh)
*
|
2021-12-17 |
2024-07-12 |
西藏海思科制药有限公司 |
一种并环杂环衍生物及其在医药上的应用
|
|
US12122764B2
(en)
|
2021-12-22 |
2024-10-22 |
Gilead Sciences, Inc. |
IKAROS zinc finger family degraders and uses thereof
|
|
KR20240123836A
(ko)
|
2021-12-22 |
2024-08-14 |
길리애드 사이언시즈, 인코포레이티드 |
이카로스 아연 핑거 패밀리 분해제 및 이의 용도
|
|
US20250049787A1
(en)
*
|
2021-12-22 |
2025-02-13 |
University Health Network |
Treatment for acute myeloid leukemia or lymphoma
|
|
WO2023138612A1
(en)
*
|
2022-01-19 |
2023-07-27 |
Silexon Ai Technology Co., Ltd. |
Heterocyclic compounds useful as hpk1 inhibitors
|
|
WO2023143384A1
(zh)
*
|
2022-01-27 |
2023-08-03 |
四川海思科制药有限公司 |
一种抑制或降解hpk1激酶的化合物及其在医药中的用途
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023151559A1
(zh)
*
|
2022-02-08 |
2023-08-17 |
和径医药科技（上海）有限公司 |
杂环化合物、包含其的药物组合物及其抗肿瘤应用
|
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
KR20240165995A
(ko)
|
2022-03-24 |
2024-11-25 |
길리애드 사이언시즈, 인코포레이티드 |
Trop-2 발현 암의 치료를 위한 병용요법
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
CR20240451A
(es)
|
2022-04-21 |
2024-12-04 |
Gilead Sciences Inc |
Compuestos de modulación de kras g12d
|
|
KR20250028371A
(ko)
|
2022-07-01 |
2025-02-28 |
길리애드 사이언시즈, 인코포레이티드 |
Cd73 화합물
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
CN117624187B
(zh)
*
|
2022-11-17 |
2025-11-04 |
杭州阿诺生物医药科技有限公司 |
一种高效的hpk1降解剂化合物及其制备方法和应用
|
|
KR102855849B1
(ko)
|
2022-11-25 |
2025-09-08 |
충남대학교산학협력단 |
이미다조피리딘 유도체, 이를 유효성분으로 포함하는 약제학적 조성물 및 이를 이용하는 암의 치료 방법
|
|
AU2023409398A1
(en)
|
2022-12-22 |
2025-06-05 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024206869A2
(en)
*
|
2023-03-30 |
2024-10-03 |
Board Of Regents, The University Of Texas System |
Combination of hpk1 inhibitor and axl inhibitor in cancer therapy
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CR20250446A
(es)
|
2023-04-21 |
2025-12-02 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CN121620513A
(zh)
|
2023-07-26 |
2026-03-06 |
吉利德科学公司 |
Parp7抑制剂
|
|
KR20260046403A
(ko)
|
2023-07-26 |
2026-04-07 |
길리애드 사이언시즈, 인코포레이티드 |
Parp7 저해제
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025080099A1
(ko)
*
|
2023-10-13 |
2025-04-17 |
주식회사유한양행 |
7,7-다이메틸푸로[3,4-b]피리딘-5(7h)-온 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
|
|
WO2025096647A1
(en)
*
|
2023-10-30 |
2025-05-08 |
Nimbus Saturn, Inc. |
Methods of treating tumors
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|